好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Machine Learning Model Predicting Presence of Leptomeningeal Metastasis
Neuro-oncology
S13 - Neuro-oncology: Advances in Diagnosis and Treatments (1:36 PM-1:48 PM)
004

We present the first random forest (RF) machine learning model to predict the likelihood of leptomeningeal metastasis (LMM) based on patient characteristics, clinical data, and cerebrospinal fluid (CSF) findings.

LMM occurs in 5-20% of patients with cancer and often portends poor prognosis, owing to delayed diagnosis. Neuroimaging and CSF testing are limited by poor sensitivity and specificity; the latter is significantly affected by disease burden and sample acquisition. Improving the diagnostic accuracy for LMM could allow for earlier treatment and potentially better outcomes.

3,518 sequential patients who underwent lumbar puncture (LP) with CSF cytological evaluation (totaling 4,197 LPs, 3.8% positive for LMM) between 2017 and 2022 across multiple hospitals in the Cleveland Clinic system were included. A two-stage RF was developed on 70% of the dataset, holding out 30% for testing. The first stage included static/slowly changing factors (e.g., malignancy history, co-morbidities) to generate a baseline risk. The second stage used the baseline risk in conjunction with dynamic variables (e.g., CSF and laboratory values). Class weighting, multiple imputation by chained equations, and model optimization using Shapley additive explanations were used to ensure model robustness.

The final model included 13 parameters (9 clinical, 3 CSF, 10 serum) and predicted LMM in the independent testing set with an area under the curve of 0.86 (sensitivity: 89%, specificity: 71%). The strongest predictors of LMM were BMI, prior malignancy type and duration, CSF corrected total nucleated cell count, and CSF lymphocyte percentage. Amongst model-predicted false positive cases, 14.4% were found by manual review to have ultimately been diagnosed with LMM by imaging or clinical course.

Clinical features predict the likelihood of LMM with acceptable sensitivity and specificity using a RF. Further multi-institutional cohorts will establish generalizability and facilitate creation of a risk scoring tool for clinical use.

Authors/Disclosures
Ryan Rilinger
PRESENTER
Mr. Rilinger has nothing to disclose.
Mina Lobbous, MD (Cleveland Clinic Foundation) Dr. Lobbous has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Servier . Dr. Lobbous has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion Pharmaceuticals . Dr. Lobbous has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Telix pharmaceuticals . Dr. Lobbous has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Springworks Pharmaceuticals . Dr. Lobbous has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Springworks Pharmaceuticals . Dr. Lobbous has received publishing royalties from a publication relating to health care.
Alyssa Lucas, MD Dr. Lucas has nothing to disclose.
Mark G. Malkin, MD, FAAN (CLEVELAND CLINIC) Dr. Malkin has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Worldwide Clinical Trials. Dr. Malkin has received publishing royalties from a publication relating to health care.
David M. Peereboom, MD Dr. Peereboom has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Anheart. Dr. Peereboom has received personal compensation in the range of $500-$4,999 for serving as a Consultant for NeOnc. Dr. Peereboom has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novocure. Dr. Peereboom has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Orbus. Dr. Peereboom has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Servier. The institution of Dr. Peereboom has received research support from Nuvation. The institution of Dr. Peereboom has received research support from Anheart. The institution of Dr. Peereboom has received research support from Pfizer. The institution of Dr. Peereboom has received research support from NeOnc. The institution of Dr. Peereboom has received research support from Bristol-Myers Squibb. The institution of Dr. Peereboom has received research support from Genentech/Roche. The institution of Dr. Peereboom has received research support from Orbus. The institution of Dr. Peereboom has received research support from GCAR.
Glen H. Stevens, DO, PhD, FAAN (Cleveland Clinic Foundation) The institution of Dr. Stevens has received personal compensation in the range of $50,000-$99,999 for serving on a Scientific Advisory or Data Safety Monitoring board for NIH. Dr. Stevens has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for EBSCO. The institution of Dr. Stevens has received research support from National Cancer Institute.
Alejandro Torres-Trejo, MD (Brain Tumor & Neuro-Oncology Center, Taussig Cancer Center, Cleveland Clinic) Dr. Torres-Trejo has nothing to disclose.
Andrew Dhawan, MD (Cleveland Clinic) Dr. Dhawan has nothing to disclose.